BR112022009273A2 - Imunoglobulinas modificadas para direcionar depósitos amiloides - Google Patents
Imunoglobulinas modificadas para direcionar depósitos amiloidesInfo
- Publication number
- BR112022009273A2 BR112022009273A2 BR112022009273A BR112022009273A BR112022009273A2 BR 112022009273 A2 BR112022009273 A2 BR 112022009273A2 BR 112022009273 A BR112022009273 A BR 112022009273A BR 112022009273 A BR112022009273 A BR 112022009273A BR 112022009273 A2 BR112022009273 A2 BR 112022009273A2
- Authority
- BR
- Brazil
- Prior art keywords
- modified
- antibody
- immunoglobulins
- amyloid
- amyloid deposits
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Abstract
IMUNOGLOBULINAS MODIFICADAS PARA DIRECIONAR DEPÓSITOS AMILOIDES. A presente invenção refere-se a imunoglobulinas modificadas compreendendo um peptídeo reativo à amiloide unido a um anticorpo, bem como anticorpos humanizados que ligam a fibrilas de amiloides humanas e proteínas de fusão anticorpo-peptídeo. A invenção ainda se refere a métodos para tratar doenças à base de amiloide administrando uma imunoglobulina modificada, um anticorpo humanizado ou uma proteína de fusão anticorpo-peptídeo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962936002P | 2019-11-15 | 2019-11-15 | |
US202063074912P | 2020-09-04 | 2020-09-04 | |
PCT/US2020/060596 WO2021097360A1 (en) | 2019-11-15 | 2020-11-13 | Modified immunoglobulins for targeting amyloid deposits |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022009273A2 true BR112022009273A2 (pt) | 2022-10-04 |
Family
ID=75912899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022009273A BR112022009273A2 (pt) | 2019-11-15 | 2020-11-13 | Imunoglobulinas modificadas para direcionar depósitos amiloides |
Country Status (11)
Country | Link |
---|---|
US (2) | US20220411489A1 (pt) |
EP (1) | EP4058479A4 (pt) |
JP (1) | JP2023502968A (pt) |
KR (1) | KR20220113950A (pt) |
CN (1) | CN115298214A (pt) |
AU (1) | AU2020385183A1 (pt) |
BR (1) | BR112022009273A2 (pt) |
CA (1) | CA3158206A1 (pt) |
IL (1) | IL292903A (pt) |
MX (1) | MX2022005850A (pt) |
WO (1) | WO2021097360A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022005850A (es) | 2019-11-15 | 2022-08-15 | Univ Tennessee Res Found | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. |
AU2021393591A1 (en) * | 2020-12-04 | 2023-07-06 | University Of Tennessee Research Foundation | Method for diagnosing amyloid diseases |
AU2022271333A1 (en) * | 2021-05-05 | 2023-11-09 | Attralus, Inc. | Peptide-fc fusions for treating amyloid disorders |
JP2024521082A (ja) * | 2021-05-18 | 2024-05-28 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | アミロイド障害を処置するための抗体-ペプチド融合タンパク質 |
WO2023043658A2 (en) * | 2021-09-14 | 2023-03-23 | Caelum Biosciences | Method of treating multiple myeloma |
WO2023220234A1 (en) * | 2022-05-11 | 2023-11-16 | Alexion Pharmaceuticals, Inc. | High sensitivity biotinylated peptide binding elisa assay |
WO2024050478A1 (en) * | 2022-09-02 | 2024-03-07 | University Of Tennessee Research Foundation | Chimeric antigen receptors for removal of amyloid |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
AU696293B2 (en) * | 1993-12-08 | 1998-09-03 | Genzyme Corporation | Process for generating specific antibodies |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ES2345746T3 (es) * | 1998-05-21 | 2010-09-30 | University Of Tennessee Research Foundation | Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide. |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
IL163851A0 (en) * | 2002-03-01 | 2005-12-18 | Immunomedics Inc | Internalizing anti-cd74 antibodies and methods of use |
EP2125893A2 (en) * | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
US10076570B2 (en) | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
US20140079691A1 (en) | 2012-09-20 | 2014-03-20 | Anaptysbio, Inc. | Thermostable antibody framework regions |
US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
US10213506B2 (en) | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
AU2018212860A1 (en) | 2017-01-30 | 2019-08-15 | National Research Council Of Canada | Blood-brain barrier transmigrating compounds and uses thereof |
EP3624842A4 (en) | 2017-06-29 | 2021-04-07 | The Trustees Of Columbia University In The City Of New York | CHIMERA ANTIBODIES FOR TREATMENT OF AMYLOID DEPOSITION DISEASES |
US11382974B2 (en) | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
US12018069B2 (en) | 2018-06-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
MX2022005850A (es) | 2019-11-15 | 2022-08-15 | Univ Tennessee Res Found | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. |
JP2024521082A (ja) | 2021-05-18 | 2024-05-28 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | アミロイド障害を処置するための抗体-ペプチド融合タンパク質 |
-
2020
- 2020-11-13 MX MX2022005850A patent/MX2022005850A/es unknown
- 2020-11-13 US US17/776,827 patent/US20220411489A1/en not_active Abandoned
- 2020-11-13 KR KR1020227019864A patent/KR20220113950A/ko unknown
- 2020-11-13 CA CA3158206A patent/CA3158206A1/en active Pending
- 2020-11-13 WO PCT/US2020/060596 patent/WO2021097360A1/en unknown
- 2020-11-13 AU AU2020385183A patent/AU2020385183A1/en active Pending
- 2020-11-13 EP EP20887541.9A patent/EP4058479A4/en active Pending
- 2020-11-13 BR BR112022009273A patent/BR112022009273A2/pt unknown
- 2020-11-13 IL IL292903A patent/IL292903A/en unknown
- 2020-11-13 CN CN202080092570.1A patent/CN115298214A/zh active Pending
- 2020-11-13 JP JP2022528305A patent/JP2023502968A/ja active Pending
-
2023
- 2023-03-09 US US18/181,489 patent/US12030934B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2023502968A (ja) | 2023-01-26 |
EP4058479A1 (en) | 2022-09-21 |
CN115298214A (zh) | 2022-11-04 |
MX2022005850A (es) | 2022-08-15 |
US20220411489A1 (en) | 2022-12-29 |
AU2020385183A1 (en) | 2022-05-26 |
EP4058479A4 (en) | 2024-02-28 |
US20230265178A1 (en) | 2023-08-24 |
CA3158206A1 (en) | 2021-05-20 |
IL292903A (en) | 2022-07-01 |
KR20220113950A (ko) | 2022-08-17 |
WO2021097360A1 (en) | 2021-05-20 |
US12030934B2 (en) | 2024-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022009273A2 (pt) | Imunoglobulinas modificadas para direcionar depósitos amiloides | |
EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
AR106754A1 (es) | Proteínas de unión a la proteína de muerte celular programada (pd1) y/o gen de activación de linfocitos 3 (lag3) | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
PE20090831A1 (es) | Anticuerpo monoclonal | |
BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
NZ701444A (en) | Antibodies to matrix metalloproteinase 9 | |
CR20120027A (es) | Polipeptidos y metodo de tratamiento | |
EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
BR112022009317A2 (pt) | Anticorpos de cd73 biparatópicos | |
PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
UA117493C2 (uk) | Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання | |
EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
CL2020002621A1 (es) | Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
MX2023013050A (es) | Proteinas de fusion anticuerpo-peptido para el tratamiento de trastornos amiloides. | |
EA202091577A1 (ru) | Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител | |
PE20190633A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
CO2018012652A2 (es) | Anticuerpos anti-fcrn madurados de afinidad humanizada |